Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.82
0.0000
Post-market: 1.81-0.0123-0.68%19:30 EDT
Volume:2.32M
Turnover:4.23M
Market Cap:808.08M
PE:-11.47
High:1.87
Open:1.85
Low:1.80
Close:1.82
52wk High:2.68
52wk Low:1.10
Shares:444.00M
Float Shares:220.42M
Volume Ratio:0.53
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1587
EPS(LYR):-0.1387
ROE:-40.21%
ROA:-14.32%
PB:4.63
PE(LYR):-13.13

Loading ...

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate

Benzinga Earnings
·
Aug 06

Lexicon Q2 FY26 Net Loss Widens to $31.8 Million; Revenue Drops to $0.7 Million

Reuters
·
Aug 06

Lexicon Pharmaceuticals Q2 Basic EPS USD -0.07

THOMSON REUTERS
·
Aug 06

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
Aug 06

Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 30

Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating

TIPRANKS
·
Jul 27

Lexicon completes enrollment in SONATA-HCM study

TIPRANKS
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment

MT Newswires Live
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)

Reuters
·
Jul 27

Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027

THOMSON REUTERS
·
Jul 27

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)

Simply Wall St.
·
Jul 02

Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions

Reuters
·
Jun 03

Lexicon Pharmaceuticals’ Earnings Call Highlights Milestone-Fueled Surge

TIPRANKS
·
Jun 02

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Stock Track | Lexicon Pharmaceuticals Soars 5.63% Intraday on Investor Conference Participation Announcement

Stock Track
·
May 12

Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference

Reuters
·
May 12

Lexicon Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
May 11